Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure

What Was Tested

This randomized controlled trial paper looks at Vasopressin.

Diuretics are frequently required to treat fluid retention in patients with congestive heart failure (CHF).

Unfortunately, they can lead to a decline in renal function, electrolyte depletion, and neurohumoral activation.

Who Took Part

The study group was 14 patients.

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

Renal and neurohumoral effects of tolvaptan and furosemide were assessed in an open-label, randomized, placebo-controlled crossover study in 14 patients with NYHA II-III CHF.

How the Study Was Run

The design is described as randomized, open-label, placebo-controlled and crossover.

Random assignment meant chance, not the researchers, decided who got Vasopressin and who got the comparison, which limits bias.

Nothing was hidden in this open-label Vasopressin study: the patients and staff both knew the treatment.

The comparison arm used a placebo, so changes seen with Vasopressin could be set against what happens without it.

Each person switched between Vasopressin and the comparison at some point, usually with a gap in between.

What Was Measured

PubMed files the paper under topics including Antidiuretic Hormone Receptor Antagonists, Benzazepines, Diuretics, Furosemide, Heart Failure, Hemodynamics and Kidney.

What This Means in Plain Language

The paper is a randomized, open-label and placebo-controlled study of Vasopressin in 14 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2006 (American journal of physiology. Renal physiology), a journal based in United States.

More context: the Vasopressin compound page, all human trials.